Publication
Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.
Liming Yu, Changnian Li, Dadong Guo, Siyuan Cui
Frontiers in immunologyJan 1, 2026PMID 42746158doi:10.3389/fimmu.2026.1932951 PMC13575964Journal ArticleReviewpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Anti-CD38 monoclonal antibodies have become a central immunotherapeutic platform in multiple myeloma, where they have reshaped treatment across relapsed or refractory disease, frontline therapy, maintenance intensification, and minimal residual disease-oriented management. Their success in multiple…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.